Healios K.K (TYO:4593) said it made progress on its application for conditional approval of its MultiStem ARDS treatment in Japan after agreeing with regulators on manufacturing details, according to a Thursday filing on the Tokyo Stock Exchange.
Clinical aspects of the application will be discussed with regulators in mid-January 2025.
Price (JPY): $167.00, Change: $+3.0, Percent Change: +1.83%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.